Summary
The cancer chemotherapeutic efficacy of the topoisomerase I inhibitor, CPT-11 (irinotecan) is often limited by the induction of severe delayed diarrhoea. In animal studies, CPT-11 use is associated with histopathological damage to the mucosa of the small and large intestines. Results from the present study demonstrate that 60 mg CPT-11 per kg body weight (i.v. q4d × 6) halted the growth, but did not cause significant regression, of MCF7 human breast carcinoma xenografts in mice fed a diet containing 7% corn oil. However, when the diet of the MCF7-bearing mice was supplemented with 3% or 6% fish oil, the same CPT-11 treatment caused significant regression of the MCF7 xenograft. Histomorphometric analyses of intestinal mucosa of mice treated with CPT-11 and fed the diet containing 7% corn oil indicated that treatment with CPT-11 induced structural changes in the intestinal mucosa which persisted at least 5 days after the last dose of CPT-11. The intestinal mucosal architecture of mice that were treated with CPT-11 and fed the diets containing fish oil was largely unchanged from the architecture of the group of mice which did not receive CPT-11. These findings indicate that fish oil supplements may be a useful adjunct to CPT-11 treatment.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abigerges, D, Armand, J-P & Chabot, GG et al (1994). Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86: 446–449.
Anti, M, Marra, G, Armelao, F, Bartoli, GM, Ficarelli, R, Percesepe, A, De Vitis, I, Maria, G, Sofo, L, Rapaccini, GL, Gentiloni, N, Piccioni, E & Miggiano, G (1992). Effect of Ω-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastro 103: 883–891.
Barnes, CJ, Lee, M, Hardman, WE & Cameron, IL (1997). NSAID modulation of colonic epithelial cell proliferation and apoptosis as intermediate biomarkers of induced rat colon cancer. Br J Cancer 77: 573–580.
Bartram, H, Gostner, A, Scheppach, W, Reddy, BS, Rao, CV, Dusel, G, Richter, F, Richter, A & Kasper, H (1993). Effects of fish oil on rectal cell proliferation, mucosal fatty acids, and prostaglandin E2, release in healthy subjects. Gastro 105: 1317–1322.
Bradford, MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.
Cao, S, Black, JD, Troutt, AB & Rustum, YM (1998). Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 58: 3270–3274.
Colvin, OM, Cokgor, I, Ashley, DM, Kerby, T, Arbuck, S, Malczyn, J, Miller, L, Cloughesy, T, Houghton, PJ, Rich, J, Friedman, AH & Friedman, HS (1998). Irinotecan treatment of adults with recurrent or progressive malignant glioma. Proc Am Soc Clin Oncology 16: (Abstract)
Esterbauer, H, Schaur, RJ & Zollner, H (1991). Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Rad Biol Med 11: 81–128.
Gerrits, CJH, de Jonge, MJA, Schellens, JHM, Stoter, G & Verweij, J (1997). Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 76: 952–962.
Hardman, WE, Barnes, CJ, Knight, CW & Cameron, IL (1997). Effects of iron supplementation and ET-18-OCH3 on MDA-MB 231 breast carcinomas in nude mice consuming a fish oil diet. Br J Cancer 76: 347–354.
Horrobin, DF (1994). Unsaturated lipids and cancer. In: New Approaches to Cancer Treatment: Unsaturated Lipids and Photodynamic Therapy, Horrobin DF, Churchill Livingstone: London, 3–29.
Ikuno, N, Soda, H, Watanabe, M & Oka, M (1995). Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 87: 1876–1883.
Kase, Y, Hayakawa, T, Aburada, M, Komatsu, Y & Kamataki, T (1997a). Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat. Jpn J Pharmacol 75: 407–413.
Kase, Y, Hayakawa, T, Togashi, Y & Kamataki, T (1997b). Relevance of irinotecan hydrochloride diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats. Jpn J Pharmacology 75: 399–405.
Kawato, Y, Aonuma, M, Hirota, Y, Kuga, H & Sato, K (1991). Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187–4191.
Mosby’s Complete Drug Reference (1997). Physicians GenRx-Drug Information, Atropine sulfate. II-175-II-177. Edited by Publisher: Ladig D. Mosby-Year Book: St Louis.
Mosby’s Complete Drug Reference (1997). Physicians GenRx-Drug Information, Loperamide hydrochloride. II-1286-II-1287. Edited by Publisher: Ladig D. Mosby-Year Book: St Louis.
Narita, M, Nagai, E, Hagiwara, H, Aburada, M, Yokoi, T & Kamataki, T (1993). Inhibition of β-glucoronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica 23: 5–10.
Potten, CS (1992). The significance of spontaneous and induced apoptosis in the gastrointestinal tract of mice. Cancer Metast Rev 11: 179–195.
Rivory, LP (1996). Irinotecan (CPT-11): a brief overview. Clin and Exp Pharmacol and Physiol 23: 1000–1004.
Rivory, LP, Bowles, MR, Robert, J & Pond, SM (1996). The conversion of CPT-11 (irinotecan) to its active metabolite, SN-38, by human liver carboxylesterase. Biochem Pharmacol 52: 1103–1111.
Rothenberg, M (1996). The current status of irinotecan (CPT-11) in the United States. Ann NY Acad Sci 803: 272–281.
Sadzuka, Y & Hirota, S (1997). Effect of CPT-11 on lipid peroxidation level in mouse tissues. Jpn J Cancer Res 88: 512–516.
Sakai, H, Diener, M, Gartmann, V & Takeguchi, N (1995). Eicosanoid-mediated Cl–secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon. Naunyn-Schmiedeberg’s Arch Pharmacol 351: 309–314.
Sakai, H, Sato, T, Hamada, N, Yasue, M, Ikari, A, Kakinoki, B & Takeguchi, N (1997). Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl–secretion in isolated rat colon. J Physiol 505.1: 133–144.
Sawada, S, Okajima, S, Aiyama, R, Nokota, K, Furuta, T, Yokokura, T, Sugini, E, Yamaguchi, K & Miyasaka, K (1991). Synthesis and antitumor activity of 20(S)-camptothecin derivatives. Carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydrocamptothecin. Chem Pharm Bull 39: 1446–1454.
Shinohara, H, Killion, J, Kuniyasu, H, Kumar, R & Fidler, IJ (1998). Prevention of intestinal toxic effects and intensification of irinotecan’s therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002. Clin Cancer Res 4: 2053–2063.
Takasuna, K, Kasai, Y, Kitano, Y, Kakihata, K, Hirohashi, M & Nomura, M (1995). Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11) in rats. Folia Pharmacol Jpn 105: 447–460.
Takasuna, K, Hagiwara, T, Kato, M, Namoru, M, Nagai, E, Yokoi, T & Kamataki, T (1996). Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56: 3752–3757.
Weber, PC & Sellmayer, A (1990). Modification of the prostanoid system and cell signalling by precursor fatty acids. Adv Prostaglandin, Thrombox Leukotri Res 21: 217–224.
Author information
Authors and Affiliations
Additional information
Correspondence to: WE Hardman
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Hardman, W., Moyer, M. & Cameron, I. Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects. Br J Cancer 81, 440–448 (1999). https://doi.org/10.1038/sj.bjc.6690713
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690713
Keywords
This article is cited by
-
Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague–Dawley rats
Cancer Chemotherapy and Pharmacology (2017)
-
Downregulation of ABCE1 via siRNA affects the sensitivity of A549 cells against chemotherapeutic agents
Medical Oncology (2015)
-
Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial
British Journal of Cancer (2009)
-
Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model
Breast Cancer Research and Treatment (2009)
-
NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells
Breast Cancer Research and Treatment (2008)